189 related articles for article (PubMed ID: 25487084)
21. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.
Cirillo I; Vaccaro N; Turner K; Solanki B; Natarajan J; Redman R
J Clin Pharmacol; 2009 Jul; 49(7):798-806. PubMed ID: 19553404
[TBL] [Abstract][Full Text] [Related]
22. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data.
Yoshizawa K; Ikawa K; Ikeda K; Kumon H; Ohge H; Morikawa N
Int J Antimicrob Agents; 2012 Nov; 40(5):427-33. PubMed ID: 22877766
[TBL] [Abstract][Full Text] [Related]
23. Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF).
Hidaka S; Goto K; Hagiwara S; Iwasaka H; Noguchi T
Yakugaku Zasshi; 2010 Jan; 130(1):87-94. PubMed ID: 20046071
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function.
Kim SW; Choe S; Kim DJ; Zang DY; Lee DH
Ther Drug Monit; 2018 Aug; 40(4):425-434. PubMed ID: 29746394
[TBL] [Abstract][Full Text] [Related]
25. Prediction of Pharmacokinetics and Pharmacodynamics of Doripenem in Pediatric Patients.
Matsuo Y; Ishibashi T; Shimamura K; Wajima T
J Pharm Sci; 2015 Sep; 104(9):3194-8. PubMed ID: 25821174
[TBL] [Abstract][Full Text] [Related]
26. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
Lewis SJ; Kays MB; Mueller BA
J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.
Xu H; Zhou W; Zhou D; Li J; Al-Huniti N
J Clin Pharmacol; 2017 Mar; 57(3):336-344. PubMed ID: 27530649
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of a pharmacokineticpharmacodynamic approach using software to optimize the carbapenem antibiotic regimen.
Ishihara N; Nishimura N; Tamaki H; Karino F; Miura K; Isobe T; Ikawa K; Morikawa N; Naora K
Int J Clin Pharmacol Ther; 2015 Jun; 53(6):422-9. PubMed ID: 25828635
[TBL] [Abstract][Full Text] [Related]
29. Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on site-specific pharmacokinetic-pharmacodynamic evaluation.
Nakamura K; Ikawa K; Yamada Y; Arakawa M; Zennami K; Nishikawa G; Ikeda K; Morikawa N; Honda N
J Chemother; 2012 Feb; 24(1):32-7. PubMed ID: 22546722
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation.
Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T
Diagn Microbiol Infect Dis; 2008 Nov; 62(3):292-7. PubMed ID: 18703305
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic/pharmacodynamic modeling and simulation to determine effective dosage regimens for doripenem.
Katsube T; Yano Y; Wajima T; Yamano Y; Takano M
J Pharm Sci; 2010 May; 99(5):2483-91. PubMed ID: 19904828
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.
Van Wart SA; Andes DR; Ambrose PG; Bhavnani SM
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):409-14. PubMed ID: 19249182
[TBL] [Abstract][Full Text] [Related]
33. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
Ramon-Lopez A; Allen JM; Thomson AH; Dheansa BS; James SE; Hanlon GW; Stewart B; Davies JG
J Antimicrob Chemother; 2015 Mar; 70(3):882-90. PubMed ID: 25362574
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges.
Nalda-Molina R; Dokoumetzidis A; Charkoftaki G; Dimaraki E; Margetis K; Archontaki H; Markantonis S; Boutos N; Sakas D; Vryonis E; Skoutelis A; Valsami G
J Antimicrob Chemother; 2012 Jul; 67(7):1722-9. PubMed ID: 22457313
[TBL] [Abstract][Full Text] [Related]
35. Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age.
Cirillo I; Vaccaro N; Castaneda-Ruiz B; Redman R; Cossey V; Bradley JS; Allegaert K
Antimicrob Agents Chemother; 2015 Aug; 59(8):4742-9. PubMed ID: 26014957
[TBL] [Abstract][Full Text] [Related]
36. Clinical pharmacology of carbapenems in neonates.
Pacifici GM; Allegaert K
J Chemother; 2014 Apr; 26(2):67-73. PubMed ID: 24090536
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy.
Ide T; Takesue Y; Ikawa K; Morikawa N; Ueda T; Takahashi Y; Nakajima K; Takeda K; Nishi S
Int J Antimicrob Agents; 2018 May; 51(5):745-751. PubMed ID: 29425834
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic modeling and simulation for dose rationale of doripenem in neonates and infants.
Matsuo Y; Matsumoto S; Wajima T; Matsubara K
Drug Metab Pharmacokinet; 2020 Feb; 35(1):145-150. PubMed ID: 31969257
[TBL] [Abstract][Full Text] [Related]
39. Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men.
Cirillo I; Mannens G; Janssen C; Vermeir M; Cuyckens F; Desai-Krieger D; Vaccaro N; Kao LM; Devineni D; Redman R; Turner K
Antimicrob Agents Chemother; 2008 Oct; 52(10):3478-83. PubMed ID: 18644951
[TBL] [Abstract][Full Text] [Related]
40. Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients.
Yamada Y; Ikawa K; Nakamura K; Mitsui K; Narushima M; Hibi H; Ikeda K; Morikawa N; Honda N
Int J Antimicrob Agents; 2010 May; 35(5):504-6. PubMed ID: 20188521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
